How to Simplify Your Reimbursement Process for the AffloVest

Published in Respiratory & Sleep on April 01, 2026

By Kathy Boland, CDME, LPN, Payer Relations Manager, Tactile Medical 

Navigating reimbursement requirements for airway clearance therapies can be complex, especially when working across a wide range of diagnoses and payer policies. To support clinicians, care teams, and payer partners, Tactile Medical has streamlined the process for determining medical necessity and documentation standards for the AffloVest. With nearly 80 ICD-10 codes now qualifying for coverage, it is easier than ever to identify appropriate candidates and ensure supporting documentation aligns with payer expectations. The following guidance outlines the diagnostic categories, clinical indicators, and best practice documentation needed to facilitate accurate, efficient reimbursement and help patients access the therapy they need. 

Summary of Qualifying ICD-10 Codes by Category  

  • Cystic fibrosis (2) 
  • Bronchiectasis (4) 
  • Infectious/immune (1) 
  • Neuromuscular/motor neuron (11) 
  • Poliomyelitis (2) 
  • Multiple sclerosis (8) 
  • Disorders of the diaphragm (1) 
  • Myotonic/metabolic (7) 
  • Muscular dystrophies (15) 
  • Quadriplegia (6) 
  • Myopathies (21) 
  • Myasthenia gravis (2) 

Qualification for Patients for the AffloVest 

It depends on what diagnosis or clinical manifestations that are specific to the patient and qualifying diagnosis.

With clinical evaluation in all patients, we should consider the symptoms that describe why a patient may need airway clearance therapy, such as the AffloVest.  

Symptoms to Consider: 

  • Chronic cough
  • Mucus retention, mucus plugging 
  • Frequent lung infections and pneumonia with antibiotic and/or steroid intervention
  • Weak, ineffective cough that does not offer the ability to clear secretions
  • Increased work of breathing with use of accessory muscles
  • Aspiration, dysphagia

Bronchiectasis is the only diagnosis that has specific criteria, which includes:

  • Diagnostic testing: CT of chest scan with interpretation supporting diagnosis.
  • Documentation of number of lung infections or hospital admissions >2 in the past year requiring antibiotic intervention.
    OR
  • Documentation of chronic daily productive cough > 6 months. Describe the nature, frequency, and onset of patient cough.
  • Documentation of tried and failed standard airway clearance therapy and outcomes, such as failed to mobilize retained secretions.
  • Best practice is noting dates and specific antibiotic interventions.

All other ICD-10 diagnosis codes require the following:

NO diagnostic testing is required for these diagnosis categories

The criteria include:

  1. Covered diagnosis
  2. Chart notes need to support the diagnosis and medical necessity within 6 months
  3. Well-documented failure of other treatments to adequately mobilize retained secretions

The diagnosis must be clearly defined within the encounter or face-to-face notes and be part of the patient’s clinical diagnostic history. It is important that the diagnostic history clearly paints a picture of how the patient’s condition has evolved and has compromised their ability to clear secretions on their own.

Additionally, there must be information in the beneficiary’s medical record that describes in detail the underlying medical conditions that cause the accumulation of pulmonary secretions, the treatment interventions (for example, chest physiotherapy, PEP, postural drainage, medications used), and the effectiveness of the treatment.

What does tried and failed look like, and how did this fail to mobilize retained secretions? 

  • Did not mobilize secretions
  • Unable to tolerate positioning (CPT)
  • Insufficient expiratory force (PEP) 
  • Physical limitations of patient or caregiver
  • Cognitive level
  • Severe arthritis/osteoporosis

Best Practice Checklist for Coverage in Review 

  • Chart notes (within 6 months) specific to patient condition, diagnosis, cough, recurrent lung infections with dates and antibiotic interventions, if applicable to diagnosis. 
  • The approved diagnosis (written out or ICD-10 code) must be in chart notes and not just on prescription. 
  • A clear picture must be painted in the chart notes of how the patient's disease has progressed to airway clearance issues, especially in disorders of the diaphragm, neuromuscular conditions, and myopathy. (Be specific, as each patient’s disease process is individual.)
  • Documentation should concentrate on the evaluation of the covered diagnosis.
  • Documentation must show that specific standard airway clearance therapy techniques or device was tried and failed to mobilize retained secretions or is not appropriate for a patient and will not be sufficient to resolve symptoms. Best practice statement: “Failed to mobilize secretions” or why it is “ineffective” or “unable to perform.” 
  • Commercial plans may have exceptions for medical necessity on additional diagnosis depending on payer and plan. 
  • E0483 (after setup) is progress notes documenting the benefit of use and continued need prior to CAP to purchase.

Reminder 

  • E0483 falls under RUL for replacement
  • E0482, E0483, and E0469 fall under same and similar 

Tactile Medical is here for you. Please contact us at afflovestinfo@tactilemedical.com or your local AffloVest representative for ongoing help and support. 


TAGS

  1. reimbursement
  2. respiratory
  3. vendor

From Our Experts

Integrated Sleep Programs in 2026: Faster OSA Care is the New Standard thumbnail Integrated Sleep Programs in 2026: Faster OSA Care is the New Standard Discover how integrated sleep programs help providers cut OSA screening-to-treatment timelines to 30 days while improving patient outcomes. The Future of Respiratory Therapy in DMEPOS thumbnail The Future of Respiratory Therapy in DMEPOS Discover the evolving role, trends, and innovations shaping the respiratory therapist's crucial impact in healthcare. Sleep Apnea Costs: An RT's Take on HME Business Challenges thumbnail Sleep Apnea Costs: An RT's Take on HME Business Challenges Discover what it costs to support a patient in the sleep apnea space and how finding a partner with a comprehensive program can help mitigate these challenges. Innovations in Nasal High Flow: The New Asymmetrical Cannula Explained thumbnail Innovations in Nasal High Flow: The New Asymmetrical Cannula Explained Flow references the delivery of high flows of humidified air and sometimes oxygen through a comfortable nasal cannula interface. The combination of flow and humidity provides four key mechanisms: airway hydration, comfort, reduction of dead space, and pressure. Redefining Respiratory Care with React Health thumbnail Redefining Respiratory Care with React Health With substantial investments in products, services, and people, React Health is more equipped than ever to meet the needs of healthcare providers and patients. Introducing F&P Nova Micro: Lightweight Comfort & Performance thumbnail Introducing F&P Nova Micro: Lightweight Comfort & Performance Fisher & Paykel Healthcare has recently announced the launch of F&P Nova Microâ„¢ nasal pillows mask for the treatment of obstructive sleep apnea (OSA) in the USA. Boone Lockard Named 2024 HomeCare Hero Finalist thumbnail Boone Lockard Named 2024 HomeCare Hero Finalist Boone Lockard was included in the HomeCare Magazine list of finalists for the 2024 HomeCare Heroes. Celebrating the Heroes of Respiratory Care: A Personal Perspective thumbnail Celebrating the Heroes of Respiratory Care: A Personal Perspective VGM's Emily Southall, Sleep Services Manager, shares what Respiratory Care Week, celebrated from October 20-26, 2024, means to her as a respiratory therapist.